RMD Stock Chart & Stats
$3841.00
$0.00(0.00%)
At close: 4:00 PM EDT
$3841.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3,099.73 - $4,776.99
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
$607.54B
Enterprise Value$31.29B
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$610.58M
Price to Earnings (P/E)20.9
Beta-0.02
Next Earnings
Jan 28, 2027EPS Estimate
56.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.99
Shares Outstanding140,639,240
10 Day Avg. Volume2
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio2.00
Price to Book (P/B)4.28
Price to Sales (P/S)4.99
P/FCF Ratio17.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4,917.01Price Target Upside28.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)227.77
Revenue Forecast (FY)$109.49B
Bulls Say, Bears Say
Bulls Say
Strong Profitability And Cash GenerationHigh margins and strong conversion of earnings into operating and free cash flow give ResMed financial flexibility to fund innovation, absorb business changes, and return capital. This durable cash engine supports resilience and reinforces the company’s ability to invest across its sleep and respiratory platforms.
Connected Ecosystem Improves AdherenceA large connected-user base and measurable adherence gains deepen ResMed’s relationship with patients and providers beyond the initial device sale. The ecosystem can support recurring resupply, strengthen customer retention, and create durable data advantages across connected care workflows.
Product Breadth And Growth OutlookReiterated growth and margin guidance indicates management expects the core portfolio to expand while becoming more profitable. New mask, bilevel, digital-health, and residential-care offerings broaden the addressable market and provide multiple avenues for sustained earnings growth.
Bears Say
Astral Discontinuation Reduces GrowthThe Astral decision removes an established revenue stream and creates a meaningful near-term drag on reported growth. Although the action addresses a field safety issue, replacing that contribution will require strength elsewhere in the portfolio and may weigh on respiratory-care scale over coming quarters.
Inflation And Expansion Costs Pressure MarginsRising component costs and facility start-up expenses can temporarily dilute operating leverage even as productivity programs support longer-term improvement. These pressures may constrain margin progression and require continued execution on procurement, manufacturing efficiency, and capacity utilization.
Free Cash Flow Has Weakened Year Over YearLower free cash flow reduces the near-term cash available for reinvestment, acquisitions, and shareholder returns, even though overall cash generation remains strong. Inventory investment and tax prepayments may normalize, but the decline signals less predictable cash conversion during the current transition.
Resmed News
RMD FAQ
What was Resmed’s price range in the past 12 months?
Resmed lowest stock price was $3099.73 and its highest was $4776.99 in the past 12 months.
What is Resmed’s market cap?
Resmed’s market cap is $607.54B.
When is Resmed’s upcoming earnings report date?
Resmed’s upcoming earnings report date is Jan 28, 2027 which is in 89 days.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Oct 29, 2026. The company reported $54.669 earnings per share for the quarter, beating the consensus estimate of $50.461 by $4.208.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed does not currently pay dividends.
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is 56.27.
How many shares outstanding does Resmed have?
Resmed has 140,639,240 shares outstanding.
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of $54.669 in its last earnings report, beating expectations of $50.461. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Resmed?
Currently, no hedge funds are holding shares in MX:RMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4,917.01 (28.01% Upside)
$4,917.01 (28.01% Upside)
Blogger Sentiment
Neutral
MX:RMD Sentiment 58%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.88%
12-Months-Change
Fundamentals
Return on Equity
25.14%
Trailing 12-Months
Asset Growth
-1.16%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Resmed
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
RMD Company Deck
RMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call had a strongly positive tone, supported by 7% core constant currency revenue growth, 14% EPS growth, gross margin expansion, record shareholder returns, product and digital health traction, and reiterated full-year guidance. The company also reported meaningful challenges, including the Astral discontinuation, sharp life support device revenue declines, inflation, lower free cash flow, transaction-related charges, and expected second-half and near-term cost pressures. Overall, the highlights significantly outweighed the lowlights.View all MX:RMD earnings summariesRMD Revenue Breakdown
51.79% Devices
35.75% Masks and other
12.46% Software as a Service
RMD Stock 12 Month Forecast
Average Price Target
$4,917.01
▲(28.01% Upside)